BACE1 and Alzheimer disease: Although the mechanism is not yet fully understood, hBM-MSCs-EVs improve AD symptoms in AD rat model by delivering miR-29c-3p to neurons, targeting BACE1 gene, and activating the Wnt/β-catenin pathway, with anti-inflammatory and neuroprotective properties [35, 36].